Approaching a damages calculation on a cross-undertaking
AstraZeneca AB & Anor v KRKA, d.d Novo Mesto and Consilient Health Ltd  EWHC 84 (Pat) relates to an application for payment of damages, further to a cross-undertaking on a preliminary injunction. The preliminary injunction in question had been ordered against Consilient in 2010, preventing it from marketing its own-brand proton pump inhibitor (PPI), Emozul. The injunction was obtained on the basis of the patent protecting AstraZeneca’s PPI product, Nexium.
However, AstraZeneca later lost a related infringement action against Ranbaxy on this patent and, as a result, concluded that it could not win at trial against Consilient. Hence, AstraZeneca applied to have the injunction discharged…
Click on the link below to read the rest of the Taylor Wessing briefing.
News from Taylor Wessing
News from The Lawyer
Briefings from Taylor Wessing
For the tax year from 6 April 2014, the standard lifetime allowance has reduced from £1.5m to £1.25m.
One of the areas highlighted last year by the Regulator was the regulation of workplace DC pension schemes.
Analysis from The Lawyer
As the equity capital markets rocketed back into favour and global M&A saw at least a partial return to form, there have been some rich pickings for The Lawyer’s Corporate Team of the Year award shortlisted firms in 2014.
The city-state is working hard to become a global wealth management hub, and law firms are gearing up for a prosperous new world